<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006103</url>
  </required_header>
  <id_info>
    <org_study_id>CALGB-9864</org_study_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>CLB-9864</secondary_id>
    <secondary_id>E-C9864</secondary_id>
    <secondary_id>CDR0000068113</secondary_id>
    <nct_id>NCT00006103</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Colorectal Cancer</brief_title>
  <official_title>Interracial Study of CPT-11 (Irinotecan) Pharmacokinetics in 5-Fluorouracil Refractory Colorectal Cancer: A Population Pharmacokinetic/Pharmacodynamic Study of CPT-11</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. It is not yet known if the effectiveness of irinotecan combined&#xD;
      with fluorouracil in treating colorectal cancer varies depending on the patient's racial&#xD;
      background.&#xD;
&#xD;
      PURPOSE: Phase III trial to study the effectiveness of irinotecan combined with fluorouracil&#xD;
      in treating patients from different racial backgrounds who have colorectal cancer that is&#xD;
      advanced, recurrent, metastatic or has not responded to treatment with fluorouracil.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the interracial differences in the pharmacokinetics of irinotecan in&#xD;
           combination with fluorouracil in terms of SN-38 glucuronidation and biliary index, and&#xD;
           gastrointestinal (GI) toxicity in patients with metastatic, locally advanced, or&#xD;
           recurrent colorectal cancer.&#xD;
&#xD;
        -  Determine if there is a significant relationship between UGT1A1 genotype (promoter&#xD;
           and/or coding region mutation) and CYP3A4 promoter genotype, vs GI toxicity, bone marrow&#xD;
           toxicity, and pharmacokinetics of irinotecan in this patient population.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to race (Asian or Pacific Islander vs black vs&#xD;
      Hispanic vs white).&#xD;
&#xD;
      Patients receive irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV on&#xD;
      days 1, 8, 15, and 22. Treatment repeats every 6 weeks for a total of 5 courses in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months for 1 year and then every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 400 patients (100 per stratum) will be accrued for this study&#xD;
      within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2000</start_date>
  <completion_date type="Actual">April 2002</completion_date>
  <primary_completion_date type="Actual">April 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>Up to 10 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>irinotecan + leucovorin + fluorouracil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive irinotecan IV over 90 minutes, leucovorin calcium IV, and fluorouracil IV on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for a total of 5 courses in the absence of disease progression or unacceptable toxicity.&#xD;
Patients are followed every 3 months for 1 year and then every 6 months thereafter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <arm_group_label>irinotecan + leucovorin + fluorouracil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <arm_group_label>irinotecan + leucovorin + fluorouracil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <arm_group_label>irinotecan + leucovorin + fluorouracil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the colon or rectum&#xD;
&#xD;
               -  Metastatic, locally advanced, or recurrent disease&#xD;
&#xD;
          -  Patients must have at least 2 generations (parents and grandparents) who belong to one&#xD;
             of the following racial groups:&#xD;
&#xD;
               -  Asian or Pacific Islander (e.g., China, Japan, Korea, the Philippine Islands, or&#xD;
                  Samoa)&#xD;
&#xD;
               -  Black (originating from the black racial groups of Africa)&#xD;
&#xD;
               -  Hispanic (originating from Mexico, Puerto Rico, Cuba, Central or South America,&#xD;
                  or other Spanish culture)&#xD;
&#xD;
               -  White (originating from the peoples of Europe, North Africa, or the Middle East)&#xD;
&#xD;
          -  No patients with parents or grandparents of mixed race or race other than that of the&#xD;
             patient&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  CTC 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST no greater than 3 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Prior adjuvant fluorouracil allowed if relapse occurred at least 6 months after&#xD;
             completion of fluorouracil&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
          -  No prior irinotecan&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent hormones except steroids for adrenal failure, hormones for nondisease&#xD;
             related conditions (e.g., insulin for diabetes), or intermittent dexamethasone as an&#xD;
             antiemetic&#xD;
&#xD;
          -  No concurrent prednisone&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy (except to bone or soft tissue involving&#xD;
             less than 25% of bone marrow)&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent phenobarbital, valproate, or cyclosporine&#xD;
&#xD;
          -  None of the following concurrently during first course of therapy:&#xD;
&#xD;
               -  Macrolide antibiotics (e.g., azithromycin, erythromycin, clarithromycin,&#xD;
                  troleandomycin, dapsone)&#xD;
&#xD;
               -  Azole antibiotics (e.g., fuconazole, miconazole, itraconazole, ketoconazole)&#xD;
&#xD;
               -  Triazobenzodiazepines (e.g., alprazolam, midazolam, triazolam)&#xD;
&#xD;
               -  Antidepressants (e.g., fluoxetine, setraline hydrochloride, fluoxamine,&#xD;
                  nefazodone hydrochloride)&#xD;
&#xD;
               -  Quinolone antimicrobials (e.g., ciprofloxacin, ofloxacin)&#xD;
&#xD;
               -  Imidazole antibiotics (e.g., clotrimazole)&#xD;
&#xD;
               -  Anti-ulcer medications (e.g., omeprazole, lansoprazole)&#xD;
&#xD;
               -  Ethinyl estradiol&#xD;
&#xD;
               -  Diltiazem&#xD;
&#xD;
               -  Cimetidine hydrochloride&#xD;
&#xD;
               -  Cisapride&#xD;
&#xD;
               -  Terfenadine&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Glucocorticoids&#xD;
&#xD;
               -  Antiepileptics&#xD;
&#xD;
               -  Grapefruit juice&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Leyland-Jones, MD</last_name>
    <role>Study Chair</role>
    <affiliation>McGill Cancer Centre at McGill University</affiliation>
  </overall_official>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>August 3, 2000</study_first_submitted>
  <study_first_submitted_qc>September 2, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2003</study_first_posted>
  <last_update_submitted>July 1, 2016</last_update_submitted>
  <last_update_submitted_qc>July 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

